# IRADIMED CORPORATION (IRMD)

> Source: Nexqual · https://nexqual.com/IRMD · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, IRADIMED CORPORATION (IRMD), nexqual.com/IRMD" · informational, not investment advice.

**Price:** USD 83.93 (-0.02% on the day) · last close of Oct 28, 2026; US market closed, not a live price. Prev close 83.95 · day 83.56–85.03 · 52w 75.75–107.9 · market cap $1.07B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $86.3M, net income $23.1M (26.7% margin), free cash flow $25.1M (SEC filings).
- Valuation: P/E 46.6x (avg 42.4x at the last 3 fiscal year-ends).
- Analysts: Buy (mean 2.33 on a 1–5 scale) (3 analysts), mean target USD 118 (range 116–120).
- Total return with dividends: 1Y +8.7% vs S&P 500 +13.6%; 5Y +147.6% vs S&P 500 +79.8%.
- Next earnings: 2026-10-30, EPS estimate USD 0.55, revenue estimate $23.4M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $41.8M | $53.3M | $65.6M | $73.2M | $83.8M | $86.3M |
| Gross profit | $32.0M | $41.3M | $50.2M | $56.4M | $64.3M | — |
| Operating income | $9.8M | $15.6M | $20.0M | $22.0M | $26.1M | $27.6M |
| Net income | $9.3M | $12.8M | $17.2M | $19.2M | $22.5M | $23.1M |
| EPS (diluted) | $0.74 | $1.02 | $1.35 | $1.50 | $1.75 | — |
| Free cash flow | $10.8M | $9.2M | $6.0M | $17.6M | $17.2M | $25.1M |
| Gross margin | 76.6% | 77.4% | 76.5% | 76.9% | 76.7% | — |
| Operating margin | 23.5% | 29.3% | 30.6% | 30.0% | 31.2% | 31.9% |
| Net margin | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% | 26.7% |
| Revenue growth | +31.8% | +27.5% | +23.0% | +11.7% | +14.4% | — |
| Cash + short-term investments | $62.5M | — | — | $52.2M | $51.2M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 46.6x · P/S 12.4x · P/FCF 42.7x · P/B 10.6x · FCF yield 2.34% · Earnings yield 2.15% · Dividend yield (paid, TTM) 1.48%
P/E at fiscal year-ends: Dec 2025 55.6x, Dec 2024 36.6x, Dec 2023 35.1x.

## Analysts
Consensus Buy (mean 2.33 on a 1–5 scale), 3 analysts; mean target USD 118 (low 116, high 120).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | Needham | Initiated | Hold |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +8.7% | +147.6% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +8.7% | +19.8% |
| Volatility (annualized) | 29.6% | 36.8% |
| Max drawdown | -21.8% (Mar 2026→Sep 2026) | -45.7% (Mar 2022→Oct 2022) |

## Peers (Medical Devices)
ATEC (Alphatec Holdings, Inc.) USD 11.45 +5.34% · INSP (Inspire Medical Systems, Inc.) USD 70.97 -0.46% · ESTA (Establishment Labs Holdings Inc) USD 68.97 +3.02% · BFLY (Butterfly Network, Inc.) USD 7.81 +5.83% · UFPT (UFP Technologies, Inc.) USD 286 -3.00% · TMDX (TransMedics Group, Inc.) USD 66.9 -4.06%

## More
Full page: https://nexqual.com/IRMD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Total devices revenue | $13.8M | 67.7% | -5.2% |
| — MRI Compatible Patient Vital Signs Monitoring Systems (part of Total devices revenue) | $6.7M | 32.6% | +12.1% |
| — MRI Compatible IV Infusion Pumps (part of Total devices revenue) | $6.4M | 31.4% | -21.5% |
| — Ferro Magnetic Detection Systems (part of Total devices revenue) | $756,000 | 3.7% | +56.8% |
| Disposables | $4.8M | 23.4% | +14.0% |
| Services and other | $1.1M | 5.2% | +6.7% |
| Amortization of extended maintenance agreements | $758,000 | 3.7% | +28.0% |
| Total revenue | $20.5M | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $16.7M | 81.7% | -8.1% |
| International | $3.7M | 18.3% | +68.8% |
| Total revenue | $20.5M | 100% | — |

## Company outlook (8-K filed 2026-05-01)

- "We expect significant shipments to begin in the second quarter of 2026 as we transition our customers to the new platform, with the third quarter reflecting the full impact of 3870 shipments and revenue growth accelerating through the back half of the year."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.55 | $0.54 | +1.9% | $23.4M | 3 |
| Next quarter (ends 2026-12-31) | $0.63 | $0.60 | +4.1% | $26.2M | 3 |
| Current fiscal year (ends 2026-12-31) | $2.11 | $2.08 | +1.8% | $92.1M | 3 |
| Next fiscal year (ends 2027-12-31) | $2.45 | $2.35 | +4.2% | $104.1M | 3 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-10-30): ±8.4%; last 8 reports averaged ±8.5%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 23 | 41.3% | ±8.4% |
| 2026-12-18 | 51 | 36.6% | ±11.0% |
| 2027-01-15 | 79 | 33.9% | ±12.7% |
| 2027-04-16 | 170 | 34.4% | ±18.7% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| May 1, 2026 | Quarter ended Mar 31, 2026 | $0.49 | $0.45 | Beat +8.9% | +1.8% |
| Feb 10, 2026 | Quarter ended Dec 31, 2025 | $0.54 | $0.48 | Beat +12.5% | +7.4% |
| Nov 3, 2025 | Quarter ended Sep 30, 2025 | $0.47 | $0.46 | Beat +2.2% | +12.9% |
| Aug 1, 2025 | — | — | — | — | +21.2% |
| May 5, 2025 | — | — | — | — | -4.6% |
| Feb 13, 2025 | — | — | — | — | -8.7% |
| Jan 10, 2025 | — | — | — | — | -2.9% |
| Oct 31, 2024 | — | — | — | — | -8.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).